Mediwound Ltd (MDWD)
Healthcare
Biotechnology
14.70 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
0.2Mrd. $
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
13Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
69.3%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.1
Performance
Perf. 1M
Price performance over the last month.
3.60%
Perf. 3M
Price performance over the last 3 months.
0.20%
Perf. 6M
Price performance over the last 6 months.
-20.10%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-23.80%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-31.4%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
35.0
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
4.5
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
13.6
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
-6.3
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
19.6%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-180.3%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-71.8%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-23.5%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.2
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
–
weak
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
2 von 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
-62.70%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
0.00%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
-16.14%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
36.26%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.90%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
14
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
42
weak
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
2 von 9
Fundamental Rating
Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.
D (-39 von 100)
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
–
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.30 | – | 6 | 9.40 | -66.90 | -2 | -2 |
| 2025: Q1 | -0.06 | – | 4 | -20.30 | -18.40 | -4 | -5 |
| 2025: Q2 | -1.04 | – | 6 | 12.70 | -233.30 | -6 | -7 |
| 2025: Q3 | -0.21 | – | 5 | 24.70 | -48.80 | -3 | -4 |
| 2025: Q4 | -0.56 | – | 2 | -68.00 | -384.70 | -3 | -6 |
| 2026: Q1 | -0.23 | – | 2 | -62.70 | -200.10 | -7 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
MediWound Ltd., ein biopharmazeutisches Unternehmen, entwickelt, fertigt und vermarktet neuartige, biotherapeutische, nicht-chirurgische Lösungen zur Gewebereparatur und -regeneration in den USA, Deutschland, Italien, Spanien und international.
| Employees | 121 |
|---|---|
| Headquarters | Yavne, Israel |
| Website | mediwound.com |
| IPO Date | 20. Mar 2014 |
| Next Earnings | 13. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ofer Gonen B.Sc. | Chief Executive Officer | 1973 |
| Hani Luxenburg | Chief Financial Officer | 1974 |
| Shmulik Hess Ph.D. | COO & Chief Commercial Officer | 1974 |
| Yaron Meyer Adv. | Executive VP, General Counsel & Corporate Secretary | 1979 |
| Ety Klinger MBA, Ph.D. | Chief Medical Officer | 1962 |
| Liron Gal | Vice President of Manufacturing Science & Technology | – |
| Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | 1967 |
| Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Senior Vice President of Global Medical Affairs | 1951 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.